Read by QxMD icon Read

Eye anti-VEGF

Samaneh Sepahi, Seyed Ahmad Mohajeri, Seyedeh Maryam Hosseini, Elham Khodaverdi, Nasser Shoeibi, Maral Namdari, Sayyed Abolghasem Sajadi Tabassi
OBJECTIVE: Diabetic macular edema (DME) is one of the most important sight-threatening complications in patients with diabetes. Due to neuroprotective properties, crocin, as the main constituent in saffron, is thought to be useful in the treatment and prevention of diabetic maculopathy. The aim of this trial was to evaluate the effects of crocin as a supplement on reducing inflammation in patients with diabetic maculopathy. DESIGN: Double blind, placebo controlled, phase 2 randomized clinical trial...
March 14, 2018: American Journal of Ophthalmology
Vincent Daien, Vuong Nguyen, Nigel Morlet, Jennifer J Arnold, Rohan W Essex, Stephanie Young, Alex Hunyor, Mark C Gillies, Daniel Barthelmes
PURPOSE: To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD). DESIGN: Retrospective, matched case-control study. METHODS: We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (three per case) matched for treatment duration before cataract surgery, baseline VA, age and length of follow-up...
March 14, 2018: American Journal of Ophthalmology
Longli Zhang, Yifeng Ke, Wei Wang, Xueying Shi, Kaiwen Hei, Xiaorong Li
PURPOSE: The current treatment approaches for Coats' disease by intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents (ranibizumab or conbercept) combined with laser therapy were evaluated for the efficacy during the treatment. METHODS: The medical records of 28 patients diagnosed with Coats' disease followed by the treatment with intravitreal injection of anti-VEGF agents and laser therapies at Tianjin Medical University Eye Hospital and Hebei Eye Hospital during July 2012 and October 2017 were reviewed retrospectively...
March 16, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
Tracy W Krick, Neil M Bressler
PURPOSE OF REVIEW: To present some recent clinically relevant results from Diabetic Retinopathy Clinical Research (DRCR) Network trials that may guide management of diabetic macular edema (DME) or proliferative diabetic retinopathy (PDR). RECENT FINDINGS: Among eyes with DME and visual acuity 20/50 or worse, aflibercept, on average, had greater improvement in visual acuity over 2 years compared with bevacizumab or ranibizumab. Aflibercept is associated with higher rates of improvements in diabetic retinopathy severity among eyes with PDR and vision-impairing DME at baseline compared with bevacizumab or ranibizumab...
March 9, 2018: Current Opinion in Ophthalmology
Alexandra Miere, Hassiba Oubraham, Francesca Amoroso, Pauline Butori, Polina Astroz, Oudy Semoun, Elsa Bruyere, Alexandre Pedinielli, Manar Addou-Regnard, Camille Jung, Salomon Y Cohen, Eric H Souied
Purpose: To compare the qualitative and quantitative choroidal neovascularization (CNV) changes after antivascular endothelial growth factor (anti-VEGF) therapy in treatment-naïve and treated eyes with age-related macular degeneration (AMD) using optical coherence tomography angiography (OCTA). Methods: Consecutive patients with neovascular AMD underwent multimodal imaging, including OCTA (AngioPlex, CIRRUS HD-OCT model 5000; Carl Zeiss Meditec, Inc., Dublin, OH) at baseline and at three monthly follow-up visits...
2018: Journal of Ophthalmology
Saleema Kherani, Adrienne W Scott, Adam S Wenick, Ingrid Zimmer-Galler, Christopher J Brady, Akrit Sodhi, Catherine Meyerle, Sharon D Solomon, Rimsha Shaukat, Roomasa Channa, Olukemi Adeyemo, James T Handa, Jiangxia Wang, Peter A Campochiaro
PURPOSE: To identify factors influencing visual outcome in patients with neovascular age-related macular degeneration (NVAMD) and subfoveal hemorrhage (SFH) treated with anti-vascular endothelial growth factor (VEGF) agents DESIGN: Retrospective case series METHODS: Anti-VEGF-treated eyes with SFH >1 disc area (DA) were identified (n=16) and changes in visual acuity (VA) and central subfield thickness (CST) from baseline to last follow up along with SFH area, thickness, minimum distance from fovea to SFH border, and time to resolution were determined...
February 27, 2018: American Journal of Ophthalmology
Maria Diedrichs-Möhring, Ulrike Kaufmann, Gerhild Wildner
Autoimmune diseases usually follow a relapsing-remitting or a chronic progressive course. To understand the underlying immunopathogenesis we investigated experimental Lewis rat models displaying both disease types, which were only dependent on the autoantigen peptide used for immunization. Retinal S-Antigen-peptide PDSAg induces chronic, monophasic disease, whilst interphotoreceptor retinoid-binding protein (IRBP)-peptide R14 causes a spontaneously relapsing-remitting course. R14-mediated uveitis can be re-induced by immunization; PDSAg-induced disease is even preventable by prior CFA-injection...
February 26, 2018: Progress in Retinal and Eye Research
Shaoxin Cai, Xuefei Cheng, Yi Liu, Zhizun Lin, Wei Zeng, Changshun Yang, Lihang Liu, Ozor Anthony Chukwuebuka, Weihua Li
Blood vessels are one of the major routes for the dissemination of cancer cells. Malignant tumors release growth factors such as vascular endothelial growth factor(VEGF) to induce angiogenesis, thereby promoting metastasis. Here, we report that The Drosophila Eyes Absent Homologue 1 (EYA1), which is overexpressed in colorectal tumor cells, can promote colorectal tumor angiogenesis by coordinating with the hypoxia-inducible factor 1 (HIF-1α) to increase the expression of VEGF-A. Moreover, data indicated that the enhancement of HIF-1α expression by Eya1 depended on its ability to activate the phosphatidylinositol 3-kinase (PI3K) signaling pathways to increase the phosphorylation of AKT subunits...
February 26, 2018: Experimental Cell Research
Noel Padrón-Pérez, Luis Arias, Marcos Rubio, Daniel Lorenzo, Pere García-Bru, Jaume Català-Mora, José M Caminal
Purpose: We evaluate changes in choroidal thickness after intravitreal injection (IVI) therapy for pachychoroid neovasculopathy (PNV). Methods: An observational, retrospective, consecutive case series was studied of 18 patients (18 eyes) who underwent anti-vascular endothelial growth factor (VEGF) therapy for PNV. The 18 fellow eyes in these patients were used as controls. All eyes were evaluated with swept-source optical coherence tomography (SS-OCT) and optical coherence tomography angiography (OCTA)...
February 1, 2018: Investigative Ophthalmology & Visual Science
Martin K Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S Bodmer, Silvan Locher, Michael A Thiel, Roland Rapold, Maximilian Kuhn, Lucas M Bachmann
BACKGROUND: To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. METHODS: We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye clinic in Switzerland between January 1st and December 31st 2016 who were insured in one of the two participating health insurance companies. Clinical data were extracted from the electronic health record system. The health insurers provided the health claim costs for the ophthalmologic care and the total health care costs of each patient in the observation period...
February 27, 2018: BMC Ophthalmology
Andrijana Kopić, Dubravka Biuk, Josip Barać, Maja Vinković, Tvrtka Benašić, Vlatko Kopić
Over the past decade, intravitreal injections of anti-VEGF agents have been widely used and intensively developed as a treatment option for many ophthalmological indications. Due to its availability and low cost, the most frequently used anti-VEGF agent is bevacizumab. This type of therapy is often indicated in patients with exudative age-related macular degeneration (ARMD) and diabetic macular edema (DME). If, in addition to these two conditions, patients have a diagnosis of primary open angle glaucoma (POAG), they also present with optic nerve head (ONH) retinal nerve fiber layer (RNFL) thinning...
September 2017: Acta Clinica Croatica
Marina Roizenblatt, Claudio Zett, Vinicius S Saraiva, Andre Maia, Octaviano Magalhães, Nilva S B Moraes
PURPOSE: To report a patient presenting a retinal pigment epithelial tear in which optical coherence tomography angiography enabled the visualization of subfoveal choroidal neovascularization (CNV) not evidenced by the fluorescein angiography. She was treated with 3 monthly intravitreous anti-VEGF injections and intraretinal fluid resolution occurred. METHODS: Observational case report. RESULTS: A 62-year-old Caucasian woman presented with decreased visual acuity in the right eye for 3 months...
February 21, 2018: Retinal Cases & Brief Reports
Shruti Chandra, Jay Sheth, Giridhar Anantharaman, Mahesh Gopalakrishnan
Purpose: To report regression of neovascularization and reperfusion of ischemic areas of the retina on Wide-field Digital Fluorescein Angiography following anti-vascular endothelial growth factor injections in a patient with active Proliferative Diabetic Retinopathy. Observations: Case report of sixty-one-year-old male patient with proliferative diabetic retinopathy and diabetic macular edema documented on wide field digital fluorescein angiography. The patient was treated with three intravitreal injections of ranibizumab given at monthly intervals...
March 2018: American Journal of Ophthalmology Case Reports
Andres Gonzalez, Gibran Khurshid
Purpose: This pilot study evaluated the combination of photodynamic therapy (PDT) and anti-vascular endothelial growth factor (anti-VEGF) as a treatment in patients with a pigment epithelial detachment (PED) due to exudative age-related degeneration (AMD). Methods: We analyzed seven consecutive patients between September 1, 2015 and September 1, 2017 with a PED secondary to exudative AMD who were treated with full fluence standard PDT and a series of monthly intravitreal anti-VEGF injections...
March 2018: American Journal of Ophthalmology Case Reports
Akira Hirata, Ken Hayashi, Kazuhisa Murata, Kei-Ichiro Nakamura
Purpose: The formation of macular hole after receiving anti-vascular endothelial growth factor (anti-VEGF) therapy is rare. We report a case of macular hole that occurred after intravitreal injection of an anti-VEGF agent for age-related macular degeneration (AMD) in a patient, who underwent vitrectomy combined with choroidal neovascularization (CNV) removal. Observations: A 64-year-old female with AMD affecting her right eye received an intravitreal injection of an anti-VEGF agent...
March 2018: American Journal of Ophthalmology Case Reports
Maria Diedrichs-Möhring, Sandy Niesik, Claudia S Priglinger, Stephan R Thurau, Franz Obermayr, Stefan Sperl, Gerhild Wildner
BACKGROUND: Uveitis is a potentially blinding inflammatory disease of the inner eye with a high unmet need for new therapeutic interventions. Here, we wanted to investigate the suppressive effect of the intraocular application of the small molecule dihydroorotate dehydrogenase (DHODH)-inhibitor PP-001 on experimental relapsing rat uveitis and furthermore determine its effect on proliferation and cytokine secretion of human peripheral blood lymphocytes (PBL) and human retinal pigment epithelial (RPE) cells in vitro...
February 21, 2018: Journal of Neuroinflammation
Markus Rohm, Volker Tresp, Michael Müller, Christoph Kern, Ilja Manakov, Maximilian Weiss, Dawn A Sim, Siegfried Priglinger, Pearse A Keane, Karsten Kortuem
PURPOSE: To predict, by using machine learning, visual acuity (VA) at 3 and 12 months in patients with neovascular age-related macular degeneration (AMD) after initial upload of 3 anti-vascular endothelial growth factor (VEGF) injections. DESIGN: Database study. PARTICIPANTS: For the 3-month VA forecast, 653 patients (379 female) with 738 eyes and an average age of 74.1 years were included. The baseline VA before the first injection was 0...
February 14, 2018: Ophthalmology
Andreea Moraru, Gabriela Pînzaru, Anca Moţoc, Dănuţ Costin, Daniel Brănişteanu
Purpose. The assessment of the incidence of ocular hypertension over a period of 1 year in patients treated with multiple intravitreal injections of anti-VEGF agents for neovascular AMD. Methods. The study comprised 58 eyes diagnosed with neovascular age-related macular degeneration and receiving PRN intravitreal treatment with anti-VEGF agents (bevacizumab or aflibercept). The follow-up period was 1 year. Intraocular pressure was measured by using the Goldmann applanation tonometry before the intravitreal injection, at 24 hours after the administration of the anti-VEGF agent and at 1 and 4 weeks...
July 2017: Romanian Journal of Ophthalmology
Sandra Petrus-Reurer, Hammurabi Bartuma, Monica Aronsson, Sofie Westman, Fredrik Lanner, Anders Kvanta
Geographic atrophy (GA), the late stage of dry age-related macular degeneration is characterized by loss of the retinal pigment epithelial (RPE) layer, which leads to subsequent degeneration of vital retinal structures (e.g., photoreceptors) causing severe vision impairment. Similarly, RPE-loss and decrease in visual acuity is seen in long-term follow up of patients with advanced wet age-related macular degeneration (AMD) receiving intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Therefore, on the one hand, it is fundamental to efficiently derive RPE cells from an unlimited source that could serve as replacement therapy...
January 22, 2018: Journal of Visualized Experiments: JoVE
Sean D Adrean, Siyang Chaili, Hema Ramkumar, Ash Pirouz, Scott Grant
PURPOSE: To examine the clinical results for patients with neovascular age-related macular degeneration (nAMD) who were managed with a treat-extend-stop (TES) protocol and received 50 or more injections of anti-vascular endothelial growth factor (VEGF) agents. DESIGN: Retrospective case study. PARTICIPANTS: Data for patients from a private retina practice meeting the following criteria were included: diagnosis of nAMD and having received 50 or more intravitreal injections of anti-VEGF agents...
February 10, 2018: Ophthalmology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"